Cargando…
Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between (99m)Tc-Bone-Scintigraphy and [(68)Ga]Ga-PSMA PET/CT
Purpose: Bone scintigraphy is the standard of reference in bone metastases in prostate cancer patients. However, new radiotracers employed in prostate-specific membrane antigen (PSMA)-ligands has led to the growing importance of PET/CT as diagnostic tool. The aim of our study was to investigate the...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620612/ https://www.ncbi.nlm.nih.gov/pubmed/28758969 http://dx.doi.org/10.3390/ph10030068 |
_version_ | 1783267624037122048 |
---|---|
author | Thomas, Lena Balmus, Caroline Ahmadzadehfar, Hojjat Essler, Markus Strunk, Holger Bundschuh, Ralph A. |
author_facet | Thomas, Lena Balmus, Caroline Ahmadzadehfar, Hojjat Essler, Markus Strunk, Holger Bundschuh, Ralph A. |
author_sort | Thomas, Lena |
collection | PubMed |
description | Purpose: Bone scintigraphy is the standard of reference in bone metastases in prostate cancer patients. However, new radiotracers employed in prostate-specific membrane antigen (PSMA)-ligands has led to the growing importance of PET/CT as diagnostic tool. The aim of our study was to investigate the difference between bone scan and PSMA-PET/CT for the detection of bone metastases in prostate cancer. Methods: Thirty patients with bone metastases originating from prostate cancer were examined by (99m)Tc-MDP bone scan and (68)Ga-PSMA-PET/CT within an average of 21 days. Bone scans were analyzed visually according to the number of lesions and using the software package ExiniBONE by Exini Diagnostics. PET/CT data was analyzed visually. Numbers of detected lesions were compared for the different methods for the whole patient and for different regions. In addition, results were compared to serum prostate-specific antigen (PSA), alkaline phosphatase (ALP), bone alkaline phosphatase (bALP), pro gastrin releasing peptide (pGRP) and eastern cooperative oncology group (ECOG) performance status. Results: In the bone scans, visual and semiautomatic lesion detection showed similar results with an average of 19.4 and 17.8 detected bone lesion per patient. However, in PSMA-PET/CT, on average double the numbers of lesions (40.0) were detected. The largest differences were found in the thorax and pelvis, which can be explained by the advantages of tomographic imaging. Bland-Altman analysis showed greater differences in patients with large numbers of bone metastases. Conclusion: No significant difference was found when using semiautomatic analysis compared to visual reading for bone scans. Fewer bone metastases were detected in bone scans than in PSMA-PET/CT. However, in none of our patients would the difference have led to clinical consequences. Therefore, it seems that for patients undergoing PSMA-PET/CT, there is no need to perform additional bone scans if the appropriate PET/CT protocols are applied. |
format | Online Article Text |
id | pubmed-5620612 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-56206122017-10-03 Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between (99m)Tc-Bone-Scintigraphy and [(68)Ga]Ga-PSMA PET/CT Thomas, Lena Balmus, Caroline Ahmadzadehfar, Hojjat Essler, Markus Strunk, Holger Bundschuh, Ralph A. Pharmaceuticals (Basel) Article Purpose: Bone scintigraphy is the standard of reference in bone metastases in prostate cancer patients. However, new radiotracers employed in prostate-specific membrane antigen (PSMA)-ligands has led to the growing importance of PET/CT as diagnostic tool. The aim of our study was to investigate the difference between bone scan and PSMA-PET/CT for the detection of bone metastases in prostate cancer. Methods: Thirty patients with bone metastases originating from prostate cancer were examined by (99m)Tc-MDP bone scan and (68)Ga-PSMA-PET/CT within an average of 21 days. Bone scans were analyzed visually according to the number of lesions and using the software package ExiniBONE by Exini Diagnostics. PET/CT data was analyzed visually. Numbers of detected lesions were compared for the different methods for the whole patient and for different regions. In addition, results were compared to serum prostate-specific antigen (PSA), alkaline phosphatase (ALP), bone alkaline phosphatase (bALP), pro gastrin releasing peptide (pGRP) and eastern cooperative oncology group (ECOG) performance status. Results: In the bone scans, visual and semiautomatic lesion detection showed similar results with an average of 19.4 and 17.8 detected bone lesion per patient. However, in PSMA-PET/CT, on average double the numbers of lesions (40.0) were detected. The largest differences were found in the thorax and pelvis, which can be explained by the advantages of tomographic imaging. Bland-Altman analysis showed greater differences in patients with large numbers of bone metastases. Conclusion: No significant difference was found when using semiautomatic analysis compared to visual reading for bone scans. Fewer bone metastases were detected in bone scans than in PSMA-PET/CT. However, in none of our patients would the difference have led to clinical consequences. Therefore, it seems that for patients undergoing PSMA-PET/CT, there is no need to perform additional bone scans if the appropriate PET/CT protocols are applied. MDPI 2017-07-31 /pmc/articles/PMC5620612/ /pubmed/28758969 http://dx.doi.org/10.3390/ph10030068 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Thomas, Lena Balmus, Caroline Ahmadzadehfar, Hojjat Essler, Markus Strunk, Holger Bundschuh, Ralph A. Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between (99m)Tc-Bone-Scintigraphy and [(68)Ga]Ga-PSMA PET/CT |
title | Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between (99m)Tc-Bone-Scintigraphy and [(68)Ga]Ga-PSMA PET/CT |
title_full | Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between (99m)Tc-Bone-Scintigraphy and [(68)Ga]Ga-PSMA PET/CT |
title_fullStr | Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between (99m)Tc-Bone-Scintigraphy and [(68)Ga]Ga-PSMA PET/CT |
title_full_unstemmed | Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between (99m)Tc-Bone-Scintigraphy and [(68)Ga]Ga-PSMA PET/CT |
title_short | Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between (99m)Tc-Bone-Scintigraphy and [(68)Ga]Ga-PSMA PET/CT |
title_sort | assessment of bone metastases in patients with prostate cancer—a comparison between (99m)tc-bone-scintigraphy and [(68)ga]ga-psma pet/ct |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620612/ https://www.ncbi.nlm.nih.gov/pubmed/28758969 http://dx.doi.org/10.3390/ph10030068 |
work_keys_str_mv | AT thomaslena assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct AT balmuscaroline assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct AT ahmadzadehfarhojjat assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct AT esslermarkus assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct AT strunkholger assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct AT bundschuhralpha assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct |